| Synapsin-2 (Synapsin II) | |
|---|---|
| Gene | SYN2 |
| UniProt | Q9UQN3 |
| PDB Structures | 2VU2, 2VU3 |
| Molecular Weight | ~60 kDa |
| Localization | Synaptic vesicles, presynaptic terminal |
| Protein Family | Synapsin family |
Synapsin-2 (SYN2) is a neuronal phosphoprotein belonging to the synapsin family (SYN1, SYN2, SYN3) that plays a crucial role in synaptic vesicle trafficking, neurotransmitter release, synaptogenesis, and synaptic plasticity. It is specifically enriched in presynaptic terminals where it regulates the organization and function of synaptic vesicle pools. Synapsin-2 is essential for maintaining proper synaptic communication, and its dysfunction has been implicated in various neurodegenerative and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, epilepsy, and schizophrenia [1].
Synapsin-2 is encoded by the SYN2 gene on chromosome 3p25. The protein is approximately 60 kDa and is expressed predominantly in the central nervous system, with high levels in the hippocampus, cerebral cortex, and basal ganglia. Unlike synapsin-1, which is primarily associated with excitatory glutamatergic synapses, synapsin-2 is more enriched in inhibitory GABAergic synapses, suggesting distinct roles in modulating different neurotransmitter systems.
The synapsin family proteins share a common domain structure and are phosphorylated by multiple kinases, including cAMP-dependent protein kinase (PKA), calcium/calmodulin-dependent protein kinase II (CaMKII), and mitogen-activated protein kinases (MAPKs). This phosphorylation regulates synapsin-2's interactions with synaptic vesicles and the actin cytoskeleton, dynamically controlling vesicle mobilization and release [2].
Synapsin-2 has a characteristic domain organization that mediates its diverse functions:
The protein contains multiple phosphorylation sites that serve as critical regulatory switches:
The ATP-binding domain (Domain C) is particularly important as it allows synapsin-2 to cycle between vesicle-bound and free states in an ATP-dependent manner, directly controlling the size and dynamics of the reserve pool of synaptic vesicles [3].
Synapsin-2 performs essential functions at the presynaptic terminal:
Synapsin-2 tether synaptic vesicles to the actin cytoskeleton through its domains, maintaining a reserve pool of vesicles that can be rapidly mobilized during periods of high neuronal activity. This clustering function is regulated by ATP binding and phosphorylation state.
By modulating the availability of synaptic vesicles for release, synapsin-2 directly influences neurotransmitter release probability. The protein acts as a molecular gatekeeper, controlling the transition of vesicles from the reserve pool to the active zone [1:1].
During neuronal development, synapsin-2 plays a critical role in synapse formation and stabilization. It interacts with presynaptic scaffolding proteins to organize the presynaptic terminal and establish proper synaptic contacts.
Synapsin-2 is a key regulator of both short-term and long-term synaptic plasticity. Changes in synapsin-2 phosphorylation state contribute to forms of plasticity such as paired-pulse facilitation and long-term potentiation (LTP).
During development, synapsin-2 participates in neuronal pathfinding and axon guidance, contributing to the proper wiring of neural circuits.
Synapsin-2 is significantly reduced in Alzheimer's disease brain, and this reduction correlates with the degree of synaptic loss and cognitive impairment [4]. The decline in synapsin-2:
In Parkinson's disease, synapsin-2 is altered in dopaminergic neurons of the substantia nigra [5]:
SYN2 gene polymorphisms have been associated with schizophrenia risk [6]:
Synapsin mutations cause epileptic encephalopathy:
Targeting synapsin-2 offers therapeutic potential:
Cesca F, et al. The synapsins key actors of synapse function and plasticity. Prog Neurobiol. 2010. ↩︎ ↩︎
Greengard P, et al. "The synapsins: regulators of synaptic function." Mol Neurobiol. Mol Neurobiol. 2021. ↩︎
Valtorta F, et al. Synapsins in neurotransmitter release and synaptic plasticity. J Neurochem. 2011. ↩︎
Fernandes AC, et al. Reduced synapsin-2 in Alzheimer's disease correlates with synaptic loss. J Alzheimers Dis. 2016. ↩︎
Picotti GB, et al. Synapsin-2 and Parkinson's disease dopaminergic dysfunction. Mov Disord. 2018. ↩︎
Bonini SA, et al. Synapsin-2 polymorphisms and schizophrenia risk. Transl Psychiatry. 2015. ↩︎